期刊
INTERNATIONAL IMMUNOLOGY
卷 29, 期 1, 页码 11-19出版社
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxx002
关键词
Alzheimer's disease; exosomes; extracellular vesicles; mesenchymal stem cells; neurodegenerative disease
类别
资金
- Developing Key Evaluation Technology: Manufacturing Technology for Industrialization in the Field of Regenerative Medicine by Japan Agency for Medical Research and Development
- Center of Open Innovation Network for Smart Health (COINS) initiated by the Council for Science
- Project for Cancer Research and Therapeutic Evolution (P-CREATE)
One of the pathological hallmarks of Alzheimer's disease (AD) is the presence of extracellular plaques resulting from the accumulation of beta-amyloid peptide (A beta). To date, a definitive cure for this disease is still lacking as the currently approved drugs used are mainly symptomatic treatments. The revolutionary discovery of extracellular vesicles (EVs) has shed new light on the development of disease-modifying treatments for AD, owing to their potential in delivering the therapeutic agents to the brain. The feasibility of harnessing EVs for clinical applications is highly dependent on the donor cell, which determines the intrinsic properties of EVs. The merit of mesenchymal stem cells (MSCs) as therapeutic delivery vehicles, and the proven therapeutic effects of the EVs derived from these cells, make researchers esteem MSCs as ideal producers of EVs. Therefore, MSC-derived EVs (MSC-EVs) emerge to be an appealing therapeutic delivery approach for the treatment of AD. Here, we discuss perspectives on the therapeutic strategies using MSC-EVs to treat AD and the associated challenges in clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据